|
1.
|
RJ GinsbergMK KrisJG ArmstrongCancer of
the lungPrinciples and Practice of OncologyVT DeVita JrS HellmanSA
Rosenberg4th editionLippincottPhiladelphia6736821993
|
|
2.
|
A JemalR SiegelE WardCancer statistics,
2009Ca Cancer J Clin59225249200910.3322/caac.20006
|
|
3.
|
X ZhouM TanV Stone HawthorneActivation of
the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2
overexpression predicts tumor progression in breast cancersClin
Cancer Res1067796788200410.1158/1078-0432.CCR-04-011215501954
|
|
4.
|
MA BjornstiPJ HoughtonThe TOR pathway:
target for cancer therapyNat Rev
Cancer4335348200410.1038/nrc1362
|
|
5.
|
EB BordersC BivonaPJ MedinaMammalian
target of rapamycin: biological function and target for novel
anticancer agentsAm J Health Syst
Pharm6720952106201010.2146/ajhp10002021116000
|
|
6.
|
D LiuY HuangB ChenActivation of mammalian
target of rapamycin pathway confers adverse outcome in nonsmall
cell lung
carcinomaCancer11737633773201110.1002/cncr.2595921387259
|
|
7.
|
K GatelyB Al-AlaoT DhillonOverexpression
of the mammalian target of rapamycin (mTOR) and angioinvasion are
poor prognostic factors in early stage NSCLC: a verification
studyLung
Cancer75217222201210.1016/j.lungcan.2011.06.01221802763
|
|
8.
|
Y SancakTR PetersonYD ShaulThe Rag GTPases
bind raptor and mediate amino acid signaling to
mTORC1Science32014961501200810.1126/science.115753518497260
|
|
9.
|
T ShibataS SaitoA KokubuGlobal downstream
pathway analysis reveals a dependence of oncogenic NF-E2-related
factor 2 mutation on the mTOR growth signaling pathwayCancer
Res7090959105201010.1158/0008-5472.CAN-10-038421062981
|
|
10.
|
LM SolisC BehrensW DongNrf2 and Keap1
abnormalities in non-small cell lung carcinoma and association with
clinicopathologic featuresClin Cancer
Res1637433753201010.1158/1078-0432.CCR-09-335220534738
|
|
11.
|
H SasakiY HikosakaK OkudaNFE2L2 gene
mutation in male Japanese squamous cell carcinoma of the lungJ
Thorac Oncol5786789201010.1097/JTO.0b013e3181db3dd320421815
|
|
12.
|
T ShibataT OhtaKI TongCancer related
mutations in Nrf2 impair its recognition by Keap1-Clu3 E3 ligase
and promote malignancyProc Natl Acad Sci
USA1051356813573200810.1073/pnas.080626810518757741
|
|
13.
|
Y HuY JuD LinMutation of the Nrf2 gene in
non-small cell lung cancerMol Biol RepOct12011(Epub ahead of
print).
|
|
14.
|
XM MaJ BlenisMolecular mechanisms of
mTOR-mediated translational controlNat Rev Mol Cell
Biol10307318200910.1038/nrm267219339977
|
|
15.
|
E KimP Goraksha-HicksL Liregulation of
TORC1 by Rag GTPases in nutrient responseNat Cell
Biol10935945200810.1038/ncb175318604198
|
|
16.
|
K ItohT ChibaS TakahashiAn Nef2/small Maf
heterodimer mediates the induction of phase II detoxifying enzyme
genes through antioxidant response elementsBiochem Biophys Res
Commun236313322199710.1006/bbrc.1997.69439240432
|
|
17.
|
TH RushmoreAN KongPharmacogenomics,
regulation and signaling pathways of phase I and II detoxifying
enzymesCurr Drug
Metab3481490200210.2174/138920002333717112369894
|
|
18.
|
T NgyyenCS YangCB PickettThe pathways and
molecular mechanisms regulating Nrf2 activation in response to
chemical stressFree Radic Biol
Med37433441200410.1016/j.freeradbiomed.2004.04.03315256215
|
|
19.
|
A SinghS Boldin-AdamskyRK
ThimmulappaRNAi-mediated silencing of nuclear factor
erythroid-2-related factor 2 gene expression in non-small cell lung
cancer inhibits tumor growth and increases efficacy of
chemotherapyCancer
Res6879757984200810.1158/0008-5472.CAN-08-140118829555
|
|
20.
|
T ArisawaT TaharaT ShibataNrf2 gene
promoter polymorphism and gastric
carcinogenesisHepatogastroenterology55750754200818613447
|
|
21.
|
GL SemenzaTargeting HIF-1 for cancer
therapyNat Rev Cancer3721732200310.1038/nrc1187
|
|
22.
|
J ZhouT ScmidS SchnitzerTumor hypoxia and
cancer progressionCancer
Lett2371021200610.1016/j.canlet.2005.05.028
|
|
23.
|
L WangW YueL ZhangmTOR and PTEN expression
in non-small cell lung cancer: analysis by real-time fluorescence
quantitative polymerase chain reaction and immunohistochemistrySurg
TodayNov302011(Epub ahead of print).
|
